Search results
Order by most recent / most popular / relevance
Results: 1-10 of 139
Teva Canada Innovation v. Attorney General of Canada
- Borden Ladner Gervais LLP
- -
- Canada
- -
- May 8 2013
The Patented Medicine Prices Review Board (the PMPRB) ordered Teva to pay the Crown approximately $2.4 million for selling its product at an
Intellectual property weekly abstracts bulletin
- Borden Ladner Gervais LLP
- -
- Canada
- -
- April 1 2013
The Court granted a Prohibition Order to AstraZeneca, preventing Ranbaxy from entering the market with a generic version of ompeprazole until the
Leave to appeal to the Court of Appeal Re: motion to strike pleadings granted in respect of claims to unjust enrichment, denied in respect of claims under the Trade-Marks Act
- Borden Ladner Gervais LLP
- -
- Canada
- -
- March 6 2013
In this case, Apotex has sued Eli Lilly for damages pursuant to s. 8 of the Patented Medicines (Notice of Compliance) Regulations. Eli Lilly brought a
Court of Appeal permits sampling of Apotex’s products
- Borden Ladner Gervais LLP
- -
- Canada
- -
- February 27 2013
The Court of Appeal is permitting several innovator pharmaceutical companies to obtain samples of Apotex’s drug products for destructive testing
NOC proceeding dismissed on the basis of overbreadth and a lack of sound prediction
- Borden Ladner Gervais LLP
- -
- Canada
- -
- February 13 2013
In this case, one claim of a patent was at issue in the proceeding. The claim related to the use of pregabalin or its racemate to treat pain. The
Ontario Court dismisses generic claims for unjust enrichment in s. 8 proceeding
- Borden Ladner Gervais LLP
- -
- Canada
- -
- January 30 2013
Apotex sued Abbott and Takeda for damages pursuant to s. 8 of the NOC Regulations. As part of the claim, Apotex claimed disgorgement of profits
Court dismisses NOC proceeding for mootness when NOA withdrawn
- Borden Ladner Gervais LLP
- -
- Canada
- -
- January 30 2013
Lilly brought an application for prohibition pursuant to the Patented Medicines (Notice of Compliance) Regulations. Subsequently, Teva established to
Judicial review brought outside time period and no vested right to NOC
- Borden Ladner Gervais LLP
- -
- Canada
- -
- January 23 2013
This decision relates to the consideration by the Minister of Health of Apotex’ submission for a Notice of Compliance (NOC) for omeprazole magnesium
Definition of “innovative drug” does not include variations
- Borden Ladner Gervais LLP
- -
- Canada
- -
- January 23 2013
This is an appeal by Takeda of a decision of the Court, in which the Court upheld the decision of the Minister of Health to refuse to list Takeda’s
Impeachment action in respect of expired patent allowed to continue
- Borden Ladner Gervais LLP
- -
- Canada
- -
- December 17 2012
Apotex commenced an impeachment action in respect of two patents. Warner-Lambert brought a motion seeking to dismiss the action as it related to one patent
Current Search
- Workarea - Litigation
- Workarea - Healthcare
- Author - Beverley Moore